Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Guggenheim Downgrades Honest Co to Neutral

Guggenheim analyst Laurent Grandet downgrades Honest Co (NASDAQ:HNST) from Buy to Neutral.

byBenzinga Newsdesk

March 25, 2022

1 minute read

Guggenheim analyst Laurent Grandet downgrades Honest Co (NASDAQ:HNST) from Buy to Neutral.

Mizuho Upgrades Southern to Neutral, Raises Price Target to $60.5

By Benzinga Newsdesk

Today, 3:39 AM

Mizuho analyst Paul Fremont upgrades Southern (NYSE:SO) from Underperform to Neutral and raises the price target from $55 to $60.5.

CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021

By Vandana Singh

Today, 3:39 AM

Australian biopharma CSL Ltd (OTC: CSLLY) has agreed&nb

CSLLY

Director Of Charles Schwab Makes $1.56 Million Sale

By Benzinga Insights

Today, 3:39 AM

Charles Schwab, Director at Charles Schwab (NYSE:SCHW), made a large insider sell on September 13, according to a new SEC filing.

SCHW

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More

By Shanthi Rexaline

Today, 3:39 AM

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.

ABT

Guggenheim Downgrades Honest Co to Neutral

Related Posts

Mizuho Upgrades Southern to Neutral, Raises Price Target to $60.5

CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021

Director Of Charles Schwab Makes $1.56 Million Sale

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More